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ABSTRACT 
 
Jeffrey Jon Olney: Binge-like consumption of ethanol and other salient reinforcers is blocked 
by orexin-1 receptor inhibition  
(Under the direction of Todd E. Thiele) 
 
Orexin (OX) neurons originating in the lateral hypothalamus (LH) are ideally positioned to 
modulate reward processing as they form connections with several key brain regions known 
to be involved in the reward pathway.  Consistent with these findings, a growing number of 
studies have implicated the OX system in modulating the rewarding properties of several 
drugs of abuse, including ethanol.  However, the role of the OX system in excessive binge-
like ethanol intake remains relatively unexplored.  Here we assessed the participation of the 
OX-1 receptor (OX1R) in binge-like ethanol consumption using the drinking-in-the-dark 
(DID) paradigm to model binge-like ethanol drinking in male C57BL/6J mice.  Binge-like 
ethanol and saccharin drinking following peripheral injections of 0.0, 5.0, or 10.0 mg/kg SB-
334867 (SB), a selective OX1R antagonist was examined.  Finally, mice were given 
peripheral injections of SB and open-field locomotor activity was measured. Results 
indicated that, inhibition of the OX1R via SB blunted ethanol and saccharin drinking, but did 
not alter open-field locomotor activity. Together, these data suggest that the OX system 
participates in the consumption of salient reinforcers regardless of calories without affecting 
general locomotor activity. 
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Chapter 1: Introduction 
 
In 1998, two independent research groups simultaneously discovered the existence of a 
novel peptide. de Lecea and colleagues (1998) noted that this new peptide possessed structural 
similarities to the gut-peptide, secretin, but displayed an expression pattern limited to the 
hypothalamus; thus, these researchers deemed this new peptide hypocretin (hypothalamus + 
secretin = hypocretin).  Alternatively, Sakurai and colleagues (1998) shrewdly observed that the 
peptide was located in the hypothalamus, a brain region long-known for its involvement in 
feeding behavior (Hetherington & Ranson 1940).  After demonstrating that this peptide 
possessed highly robust orexigenic properties, these researchers named this peptide orexin 
(OX).   
Cloning studies have revealed that the OX system is comprised of two peptides, orexin-
A and orexin-B, which are derived from the precursor, prepro-orexin, and act on two G-protein 
coupled receptors, OX1R and OX2R (de Lecea et al. 1998; Sakurai et al. 1998). These peptides 
interact with equal affinity at the OX2R, but orexin-A has been found to have a greater affinity 
for OX1R with orexin-B exerting minimal actions on OX1R (Sakurai et al. 1998). These 
receptors are generally excitatory and are involved in a myriad of neurobiological functions, 
such as feeding (Sakurai et al. 1998), reward-related behavior (Harris et al. 2005), stress 
(Sakamoto et al. 2004; Winsky-Sommerer et al. 2004), and arousal (Chemelli et al. 1999).  
Although central OX originates solely within the hypothalamus (Sakurai et al. 1998), its 
afferents form connections with regions across the brain (Yoshida et al. 2005). Consistent with 
these findings, OX projections originating from the lateral hypothalamus (LH) facilitate the 
activity of several brain regions in the reward circuit, such as the ventral tegmental area 
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(VTA; Korotkova et al. 2003; Borgland et al. 2006; Moorman & Aston-Jones 2010) and shell of 
the nucleus accumbens (NAc; Patyal et al. 2012).  
In agreement with the widespread connections of hypothalamic OX neurons to various 
regions in the reward circuit, OX has been found to be involved in the neurobiological responses 
to ethanol.  Lawrence and colleagues (2006) first observed this relationship by systemically 
injecting the selective orexin-1 receptor (OX1R) antagonist, SB-334867 (SB), to reduce operant 
self-administration of ethanol.  Furthermore, SB was found to selectively reduce ethanol 
consumption in high-, but not low-, ethanol preferring rats (Moorman & Aston-Jones 2009).  
Further investigations suggest that modulation of OX signaling via SB is specific to ethanol as 
Jupp and colleagues (2011) found that SB significantly attenuated the motivational effects of 
ethanol but not sucrose.  Although these data suggest an essential role for OX1R signaling in 
ethanol drinking, recent evidence suggests the OX2R antagonists are also capable of 
suppressing responses to ethanol (Shoblock et al. 2011; Anderson et al. 2014; Barson et al. 
2014).  Moreover, more comprehensive investigations of the role of OX in ethanol drinking have 
revealed that signaling within the reward-related pathway is responsible for modulating this 
behavior.  Indeed, direct infusions of orexin-A to the LH (Schneider et al. 2007) and a non-
selective OXR antagonist into the VTA (Srinivasan et al. 2012) significantly increased and 
decreased ethanol drinking, respectively.  As a whole, these findings indicate ethanol drinking 
directly parallels OX signaling in the reward pathway. 
Despite this growing body of literature implicating the OX system in ethanol 
consumption, relatively less is known of its role in binge drinking behavior.  Considering recent 
evidence that indicates different neurocircuitry may be engaged during binge-like versus 
moderate levels of ethanol drinking (Lowery et al. 2010; Lowery-Gionta et al. 2012; Sparta et al. 
2008), the goal of the present study was to further characterize the role of the central OX 
system in binge-like drinking behavior.  To this end, we peripherally administered the selective 
OX1R antagonist, SB, to characterize the participation of the OX1R in binge-like ethanol 
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consumption, and we assessed the specificity of SB in modulating ethanol drinking by 
examining its effects on saccharin, a salient but non-caloric reinforcer.  Additionally, we also 
examined the effects of this pharmacological inhibition on more general behavioral responses 
by assessing locomotor activity following treatment with SB. 
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Chapter 2: Materials and Methods 
Animals 
 A total of forty male C57BL/6J (C57) adult mice (aged 7-9 weeks; Jackson 
Laboratories, Bar Harbor, ME) were used in the present study.  Relative to other strains of mice, 
C57s have demonstrated superior drinking in the DID paradigm (Rhodes et al. 2005; Rhodes et 
al. 2007).  Mice were individually housed in plastic cages located in a vivarium with an ambient 
temperature of approximately 22ºC and a reverse light/dark cycle with lights off at 7:00 am.  
Food and water were available ad libitum except during testing (see below).  All procedures 
used were in accordance with the National Institute of Health guidelines and were approved by 
the University of North Carolina Institutional Animal Care and Use Committee.  
 
General Procedure 
Drugs 
SB-334867 (SB; 0.0, 5.0, or 10.0 mg/kg; Tocris Bioscience, Minneapolis, MN) was 
dissolved using 0.01% Tween® 80 (Sigma-Aldrich, St. Louis, MO) in saline as described 
previously (Anderson et al. 2014).  All doses were administered in a 10.0 ml/kg injection volume.  
 
Drinking-in-the-dark 
A 4-day drinking-in-the-dark (DID) procedure was used to model binge-like drinking 
(Rhodes et al. 2005). The DID procedure is a commonly used animal model of binge-like 
ethanol drinking that promotes high levels of consumption and generates physiologically 
relevant blood ethanol concentrations (BECs) of 80.0 mg/dl or greater 
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(Rhodes et al. 2005; Rhodes et al. 2007). On days 1-3, standard water bottles were removed 
three hours into the dark cycle and the animals were given access to test bottles containing 
either ethanol (20% v/v) or saccharin (0.15% w/v) solutions for two hours.  Using the standard 
DID protocol, binge-like consumption is assessed on the fourth day when access is extended to 
four hours.  However, SB has been reported to have a relatively short half-life of less than 30 
min (Porter et al. 2001).  In agreement with this report, our initial findings indicated that the 
effects of SB were rather short-lived.  Due to the hyper-transient nature of the drug, a 
shortened, modified DID procedure was used in the current experiments to better capture the 
transient effects of the drug.  Therefore, binge-like consumption was assessed on the fourth day 
when the animals were given two-hour access to the test bottles. 
Experiment 1: Binge-like Ethanol Drinking Following Treatment with SB  
In order to examine the contribution of the OX1R in binge-like ethanol drinking, animals 
were given intraperitoneal (i.p.) injections of 0.0, 5.0, or 10.0 mg/kg SB 30 min prior to ethanol 
access.  Immediately after testing, tail-blood samples were collected from each animal and 
BECs were measured using the Analox blood ethanol analyzer (Analox Instruments, Luneburg, 
MA).  In order to increase power during statistical analysis, each animal received all three doses 
of the drug over repeated trials to allow for within-subjects comparison of ethanol drinking 
behavior.  Mice were given three days rest between subsequent 4-day DID sessions in order to 
avoid carryover effects of the drug.   
Experiment 2:  Binge-like Saccharin Drinking Following Treatment with SB 
A separate cohort of 20 C57 mice was used to assess binge-like consumption of 
saccharin following treatment with SB.  The procedures used here were identical to those 
described above with the exception that these mice were given access to saccharin (0.15% w/v) 
during the modified, two-hour DID procedure and tail-blood samples were not taken from these 
animals.  All other experimental parameters remained unchanged.  A Latin square design was 
used such that each animal received all three doses of the drug over repeated trials.  Mice were 
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given three days of rest between subsequent 4-day DID sessions in order to avoid carryover 
effects of the drug.   
Experiment 3: Locomotor Activity Following Treatment with SB 
The same 20 mice from the previous saccharin experiment were used to assess 
locomotor activity following treatment with SB.  One hour before locomotor testing, animals were 
brought into a dark room adjacent to the room that housed the locomotor chambers.   Thirty 
minutes before locomotor testing, animals were given i.p. injections of 0.0 or 10.0 g/kg SB as 
described above.  The decision to use only the 10.0 mg/kg dose of SB was based on the 
findings from our previous experiment that only the higher dose produced significant reductions 
in ethanol consumption.  Three hours into the dark cycle, animals were placed in a 16.5 x 16.5 
in2 open-field locomotor chamber (Accuscan Instruments, Columbus, OH) and locomotor 
activity was recorded in five minute bins for two hours using VersaMax software (Omnitech 
Electronics, Columbus, OH).  After the two-hour test period, mice were placed back into their 
homecages and returned to the vivarium. Unlike our previous pharmacological experiments, a 
Latin square was not used in order to avoid previous experience with the locomotor chamber 
confounding the animals’ locomotor activity. 
 
Data Analysis 
For experiment 1, a repeated-measures ANOVA was used to assess hourly ethanol 
consumption with both time (hour 1 and hour 2) and SB dose (0.0, 5.0, or, 10.0 mg/kg) being 
within-subject variables.  Additionally, total ethanol consumption across the two-hour test period 
was assessed using a repeated-measures ANOVA with SB dose (0.0, 5.0, or, 10.0 mg/kg) as 
the within-subject variable.  Since the first round of DID in the within-subjects design followed 
the standard, four-hour DID model, the tail-blood samples from the first round were excluded 
from the analysis.  Due to the exclusion of these data points, a univariate ANOVA was used to 
assess BECs with dose of SB (0.0, 5.0, or 10.0 mg/kg) as the independent variable.  
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Additionally, drug order was included as a between-subjects variable in these analyses to 
ensure the order in which the animals were presented the drug did not have any confounding 
effects on ethanol consumption.  Tukey’s HSD post-hoc tests and Bonferroni corrections were 
used when applicable. 
For experiment 2, a repeated-measures ANOVA was used to assess hourly saccharin 
consumption with both time (hour 1 and hour 2) and dose of SB (0.0, 5.0, or, 10.0 mg/kg) being 
within-subject variables.  Total saccharin consumption was also assessed using separate 
repeated-measures ANOVAs with SB dose (0.0, 5.0, or, 10.0 mg/kg) as the within-subject 
variable.  Drug order was also included as a between-subjects variable in these analyses. 
Tukey’s HSD post-hoc tests and Bonferroni corrections were used when applicable. 
For experiment 3, separate t-tests were used to assess the effects of SB on locomotor 
activity.  In addition to measuring the effects of SB across the entire two-hour test period, the 
immediate effects of the drug during the first 15 min of testing were also assessed.  
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Chapter 3: Results 
Experiment 1 
Our first experiment sought to determine whether manipulating OX signaling via the 
selective OX1R antagonist, SB, could modulate binge-like ethanol drinking. As shown in Fig. 
1A, treatment with SB significantly reduced binge-like ethanol consumption (main effect of dose:  
F(2,38) = 6.083, p = 0.005) but the animals’ drinking behavior did not change over time (main 
effect of time:  F(1,19) = 0.372, p = 0.549). Analysis also showed that there was a significant drug 
by time interaction effect (F(2,38) = 8.196, p = 0.001).  Further probing revealed that both the 5.0 
and 10.0 mg/kg dose of SB significantly reduced binge-like ethanol drinking during the first hour 
relative to water (p = 0.016, p < 0.001, respectively), though the higher dose of SB significantly 
reduced binge-like ethanol drinking to a level beyond the lower dose (p = 0.015).  Importantly, 
the effect of drug order was not significant (F(2,17) = 0.862, p = 0.481) indicating that the order in 
which the animals received the SB treatment did not affect hourly ethanol drinking behavior.  
Additionally, SB significantly reduced ethanol drinking over the two-hour test period (F(2,38) = 
9.870, p < 0.001).  Interestingly, the effect of the lower dose of SB appeared to be short-lived as 
only the higher dose significantly blunted ethanol drinking over the full two hours (p < 0.001).  
This effect of the higher dose across the two-hour test period appears to be driven by the effect 
at the first hour as no differences were observed during the second hour of testing.  Similar to 
the hourly consumption, drug order did not impact total ethanol drinking behavior (F(2,17) = 0.862, 
p = 0.481).   
In accordance with the drinking data, treatment with SB significantly reduced measured 
BECs as well (Fig. 1B; F(2,59) = 4.312, p = 0.018).  Further probing of this effect indicated 
animals treated with the higher dose of SB exhibited significantly lower BECs relative to vehicle 
treated animals (p = 0.013).  Finally, order of drug presentation did not affect measured BECs 
(F(1,56) = 0.729, p = 0.539). 
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Experiment 2 
The previous experiment demonstrated that pharmacological inhibition of the OX1R is 
capable of reducing excessive ethanol consumption in a DID paradigm.  Interestingly, a recent 
study by Anderson and colleagues (2014) observed that systemic treatment with SB reduces 
binge-like sucrose consumption, which suggests the OX system modulates binge-like 
consumption of general, salient reinforcers beyond ethanol.  However, as sucrose and ethanol 
are both reinforcing substances that have calories, it remains to be seen whether or not these 
effects are due alterations in caloric need.  Thus, the next experiment sought to characterize the 
effects of SB on saccharin, a salient, non-caloric reinforcer.   
Analysis of hourly intake revealed that SB significantly reduced saccharin consumption 
(Fig. 2; main effect of dose:  F(2,38) = 4.231, p = 0.022).  Further probing of this main effect 
showed that only the higher dose (10.0 mg/kg) of SB significantly attenuated saccharin intake 
after Bonferroni’s correction (p = 0.011).  A significant main effect of time indicated that all 
animals drank more saccharin during the first hour than during the second (main effect of time:  
F(1,38) = 11.756, p = 0.003).  The dose by time interaction effect did not reach significance (F(2,38) 
=  1.089, p = 0.347).  Additionally, SB significantly reduced total saccharin intake across the full 
two-hour test period (F(2,38) = 4.231, p = 0.022).  Similar to the hourly consumption, follow-up 
tests revealed that only the higher dose of SB significantly attenuated saccharin intake after 
Bonferroni’s correction (p = 0.011).  As with the previous experiment, drug order did not affect 
hourly (F(2,17) = 0.024, p = 0.977) or total (F(2,17) = 0.018, p = 0.982) saccharin drinking behavior. 
Together, findings from this experiment indicate that the effect of reduced binge-like drinking 
following pharmacological inhibition of the OX1R via SB is not specific to ethanol but appears to 
blunt consumption of salient caloric (ethanol) and non-caloric (saccharin) reinforcers. 
Experiment 3 
Perhaps one of the most widely studied functions of the OX system is its role in sleep 
and arousal (see de Lecea 2012 for review).  To rule out the possibility that our observed effects 
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of SB on ethanol or saccharin consumption could be secondary to the effects of SB on general 
motor behavior, the next experiment sought to test the effects of SB on open-field locomotor 
activity.  Simple t-tests showed that, relative to vehicle, treatment with the 10.0 mg/kg dose of 
SB had no discernable effect on immediate locomotor activity during the first 15 min of testing 
(t(18) = 0.2129, p = 0.834) nor across the entire two-hour test period (t(18) = 1.630, p = 0.1204; 
Fig. 3).  Together, these data demonstrate that our observed effects of SB on the consumption 
of salient reinforcers are not a consequence of impaired locomotor activity.  
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Chapter 4: Discussion 
 
 The goal of the present experiments was to examine the contribution of the OX 
system in binge-like ethanol drinking.  Through our series of experiments, we demonstrated that 
blocking the OX1R signaling via SB protects against excessive ethanol consumption.  
Interestingly, this effect is not specific to ethanol as treatment with SB also reduced binge-like 
consumption of saccharin; however, no other nonspecific effects were observed as SB did not 
significantly alter locomotor activity.   
We observed that selective inhibition of the OX1R protected against excessive ethanol 
consumption using the DID procedure.  This observation confirms several others that have 
reported that prior treatment with SB significantly reduces responding to ethanol in a variety of 
paradigms (Moorman & Aston-Jones 2009; Jupp et al. 2011; Anderson et al. 2014; Voorhees & 
Cunningham 2011).  Notably, our mice exhibited robust ethanol intake yet the BEC levels were 
slightly below binge criteria, which may stem from the shortened 2 hour test.  What is more, our 
findings indicate the protective effect of SB is not specific to ethanol as we also observed that 
SB reduced excessive intake of saccharin, a non-caloric reinforcer.  In fact, it has recently been 
reported that systemic SB protects against binge-like ethanol and sucrose intake (Anderson et 
al. 2014; Alcaraz-Iborra et al. 2014).  Together with our observation that peripherally 
administered SB similarly blunts ethanol and saccharin drinking, these findings suggest the 
OX1R modulates the consumption of salient reinforcers regardless of caloric content.  Although 
previous findings have demonstrated that the protective effect of peripherally administered SB is 
specific to ethanol and not sucrose (Jupp et al. 2011), this difference could be attributed to 
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procedural differences.  That is, the prior study used operant responding to ethanol and 
sucrose in alcohol-preferring rats while the present study used the DID procedure in C57 mice. 
Moreover, the recent report by Anderson and colleagues (2014) described similar 
success in using SB to significantly reduce binge-like ethanol drinking in C57s using the 
standard DID model.  Interestingly, that same report found that only a high dose of SB (30.0 
mg/kg) reduced binge-like ethanol drinking while lower doses were ineffective.  Though the 
effective dose of SB between this previous report and our current study are at variance with one 
another, there are methodological differences that may be able to explain this disparity.  First, a 
great deal of variability in SB has been documented between different vendors and even 
different batches of the same vendor (Mahler et al. 2012; Jupp et al. 2011).  The previous study 
used SB that was synthesized by one of the researchers at Lilly Research Laboratories while 
we ordered ours from a private vendor. This may be of importance as the manner in which the 
compound is synthesized may alter its effectiveness (McElhinny et al. 2012).  Therefore, the 
possibility that the different effective dose observed between our studies is due to some 
inherent difference between the two SB compounds cannot be ruled out.   
Another difference between these two reports is the time intervals at which consumption 
data were measured.  The previous study reported that only the 30.0 mg/kg dose of SB was 
effective in significantly reducing ethanol drinking over a four-hour test period.  However, the 
rather short half-life of the SB compound (Porter et al. 2001) prompted us to shorten the test 
period as well as take hourly measures in order to assess drinking over time.  Using this design, 
we were able to discover that lower doses are indeed capable of reducing excessive ethanol 
consumption- though the effect is short-lived. 
Although this report demonstrates that inhibition of the OX system protects against 
binge-like ethanol consumption, the systemic nature of our treatment procedure is unable to 
determine the locus of this effect.  Future studies will attempt to identify the OX circuits that 
convey these effects via site-specific delivery of OX agents directly to candidate regions.  The 
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LH is known to be involved in reward-related behavior (Wise 1996; DiLeone et al. 2003) and OX 
neurons originated from the LH have been reported to project to key brain regions in the reward 
circuit (Marcus et al. 2001; Yoshida et al. 2005).  Both the NAc shell and VTA are densely 
innervated by OX neurons and are known to be involved in reward-related behavior.  Indeed, 
application of OX peptide within the shell of the NAc in vitro causes a robust depolarization 
(Mukai et al. 2009).  However, direct infusion of orexin-A into the NAc shell failed to alter ethanol 
consumption (Schneider et al. 2007) suggesting that OX signaling in this brain region may not 
modulate ethanol drinking behavior.  On the other hand, it has been previously demonstrated 
that application of orexin-A alone initiates plastic changes in the VTA that facilitate activity in this 
region (Borgland et al. 2006).  Moreover, blocking OXRs in the VTA has been shown to protect 
against ethanol self-administration (Srinivasan et al. 2012).  Taken together, these findings 
suggest the OX neurons originating in the LH that project to the VTA may be a key circuit that 
modulates ethanol drinking. 
Finally, since the OX system is known to be critically involved in sleep and arousal 
(Chemelli et al. 1999), it was important to rule out the possibility that our observed effects of SB 
on responding to salient reinforcers was not due to an induction of a hypoactive state.  Given 
that treatment with SB did not alter locomotor activity at any time point measured, it is unlikely 
that inhibiting the OX1R could have produced any effects on arousal that could have 
confounded our effects on binge-like consummatory behavior. 
Findings from the present report indicate that pharmacological inhibition of signaling onto the 
OX1R served to protect against excessive ethanol and saccharin consumption without altering 
locomotor activity.  Together, these data provide evidence for a role of the OX system in binge-
like ethanol consumption and warrant further investigation.  Future studies will investigate the 
specific brain regions exerting these effects via site-specific infusions of SB.  Moreover, though 
this study outlines a critical role for the OX1R in these behaviors, future investigations will 
characterize the role of the OX2R as well.  Additionally, the ability of OX1R inhibition to reduce 
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binge-like ethanol drinking suggests that the OX system is perturbed during this behavior; thus, 
further studies using immunohistochemistry will examine changes in the OX system following 
multiple episodes of DID. Importantly, these findings provide promise that targeting the OX 
system through OXR antagonists may serve as an effective treatment for alcohol use disorders.
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Figure 1. Pharmacological inhibition of the OX1R reduces excessive ethanol consumption and 
BEC.  Both the 5.0 mg/kg and 10.0 mg/kg doses of SB protected against excessive ethanol 
consumption during the first hour of testing relative to vehicle treated controls; however, only the 
10.0 mg/kg dose caused a significant reduction in ethanol drinking across the full two-hour test 
period (A).  Prior treatment with the 10.0 mg/kg dose of SB caused a significantly lower BEC 
relative to vehicle treated controls (B).  * denotes p < 0.05 relative to vehicle group at the same 
time point; † denotes p < 0.05 relative to 5.0 mg/kg group at the same time point. Data are 
presented as Mean ± SEM. 
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Figure 2. 
Figure 2.   Pharmacological inhibition of the OX1R reduces excessive saccharin consumption.  
Both doses of SB significantly reduced excessive saccharin drinking over the two hours of DID 
testing.  * denotes p < 0.05 relative to vehicle group at the same time point. Data are presented 
as Mean ± SEM. 
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Figure 3. Treatment with SB does not affect locomotor activity.  The 10.0 mg/kg dose of SB had 
no discernable effects on locomotor activity across the full two hours of testing nor did it have 
any immediate effects during the first 15 min of locomotor testing (inset).  Data are presented as 
Mean ± SEM. 
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